CytoPak GMP Human IL-7 Protein

DMF
No equivalent PG product available.
1/7
+4 View all
製品番号/仕様
価格
Availability
数量
CytoPak
GMP-L07H24GB01-10ug
Inquire
In Stock - Delivery in 2-3 business days
GMP lyophilized
GMP-L07H24-50ug
$1,130.00
In Stock - Delivery in 2-3 business days
GMP-L07H24-1mg (50ug X 20)
$10,890.00
In Stock - Delivery in 2-3 business days
GMP-L07H24-10mg (50ug X 200)
$76,230.00
GMP-L07H24GB01
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
IL-7 PRODUCT SHOW

CytoPak GMP Human IL-7 Protein is packaged in sterile closed containers that can be readily incorporated into ex vivo clinical production processes. The bag utilizes medical grade multilayer film with two weldable options. The outlet weldable tube contains a proximal TPE section (1/8’’ ID x 1/4’’ OD) and a distal PVC section (3/32’’ ID x 5/32’’ OD). The liquid state and closed-system packaging of CytoPak GMP Human IL-7 Protein can be directly welded to GMP media bags resulting in safety and user-friendliness by bypassing the reconstitution step during manufacture.

GMP Platform Advantages
  • Quality Assurance: Global QMS with comprehensive and stringent QC release criteria.
  • End-to-End GMP Compliance: Full manufacturing and QC under a cGMP system.
  • Comprehensive Control of Adventitious Agents: Stringent biosafety from cell banks to final release.
  • Comprehensive Regulatory Support: Includes RSF and DMF to meet global requirements.
  • Resilient Supply Chain: Intelligent modular facilities ensure a stable global supply.
  • Professional Support: Extensive manufacturing and application expertise to accelerate development.
Source

CytoPak GMP Human IL-7 Protein (GMP-L07H24GB01) is expressed from human 293 cells (HEK293). It contains AA Asp 26 - His 177 (Accession # P13232-1).

Predicted N-terminus: Asp 26

Molecular Characterization

This protein carries no "tag".

The protein has a calculated MW of 17.4 kDa. The protein migrates as 23 kDa and 28 kDa±3 kDa under reducing (R) condition (SDS-PAGE).

Endotoxin

Less than 1.0 EU/mL, tested by the LAL method in compliance with USP <85> and Ph. Eur. 2.6.14.

Host Cell Protein

<0.5 ng/µg of protein tested by ELISA.

Host Cell DNA

<0.02 ng/μg of protein tested by qPCR.

Sterility

Sterility testing was performed using the membrane filtration method in compliance with USP <71> and Ph. Eur. 2.6.1.

Mycoplasma

Negative

Purity

>95% as determined by SDS-PAGE.

Formulation

Supplied as 0.2 μm filtered solution in PBS, rHSA, pH7.4 with protectants.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Upon receipt, store it immediately at -20°C or lower for long term storage.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • Can be stored up to 24 months at -20°C;
  • Can be stored up to 2 weeks at 2-8°C.

バックグランド

Interleukin 7 is also known as IL7, IL-7, and is a hematopoietic growth factor secreted by stromal cells in the red marrow and thymus. It is also produced by keratinocytes, dendritic cells, hepatocytes, neurons, and epithelial cells, but is not produced by lymphocytes. IL-7 stimulates the differentiation of multipotent (pluripotent) hematopoietic stem cells into lymphoid progenitor cells, It also stimulates proliferation of all cells in the lymphoid lineage (B cells, T cells and NK cells). It is important for proliferation during certain stages of B-cell maturation, T and NK cell survival, development and homeostasis. IL-7 is a cytokine important for B and T cell development. This cytokine and the hepatocyte growth factor (HGF) form a heterodimer that functions as a pre-pro-B cell growth-stimulating factor. IL-7 binds to the IL-7 receptor, a heterodimer consisting of Interleukin-7 receptor alpha and common gamma chain receptor. Il-7 promotes hematological malignacies (acute lymphoblastic leukemia, T cell lymphoma). Elevated levels of IL-7 have also been detected in the plasma of HIV-infected patients. IL-7 as an immunotherapy agent has been examined in many pre-clinical animal studies and more recently in human clinical trials for various malignancies and during HIV infection. IL-7 could also be beneficial in improving immune recovery after allogenic stem cell transplant.